ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
CTI BioPharma Corporation

CTI BioPharma Corporation (CTIC)

9.09
0.00
(0.00%)
Closed March 27 04:00PM
9.09
0.00
( 0.00% )
Pre Market: 08:00PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
9.09
Bid
10.01
Ask
8.64
Volume
-
0.00 Day's Range 0.00
4.005 52 Week Range 9.10
Previous Close
9.09
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
-
Financial Volume
-
VWAP
-

CTIC Latest News

Form 15-12G - Securities registration termination [Section 12(g)]

As filed with the Securities and Exchange Commission on July 6, 2023       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 15...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
524.591024.59.14.00558662047.94018877CS
1566.26221.2014134282.839.11.4332850125.26483558CS
2608.14856.8421052630.959.10.6220925644.73038744CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 17.07
(259.37%)
325.87k
BCGBinah Capital Group Inc
$ 21.50
(126.32%)
83.39k
PIKKidpik Corporation
$ 4.93
(50.76%)
488.32k
SSKNStrata Skin Sciences Inc
$ 0.66
(48.35%)
2
KTRAKintara Therapeutics Inc
$ 0.1228
(37.21%)
5.26M
WAVDWaveDancer Inc
$ 2.93
(-18.61%)
10
UGROUrban Gro Inc
$ 1.48
(-18.46%)
393
INOInovio Pharmaceuticals Inc New
$ 10.65
(-18.27%)
33
SOBRSOBR Safe Inc
$ 0.41
(-18.00%)
1.49k
MVLAMovella Holdings Inc
$ 0.0624
(-17.35%)
9.88k
KTRAKintara Therapeutics Inc
$ 0.1232
(37.65%)
5.27M
AKBAAkebia Therapeutics Inc
$ 2.77
(23.66%)
1.88M
CISSC3is Inc
$ 0.0353
(-7.59%)
1.03M
GMDAGamida Cell Ltd
$ 0.0494
(-16.55%)
962.22k
VERBVerb Technology Company Inc
$ 0.2711
(-3.52%)
577.49k

CTIC Discussion

View Posts
Frankestin Frankestin 10 months ago
Started this too!
https://clinicaltrials.gov/ct2/show/NCT04858256?cond=pacritinib&draw=2&rank=1
๐Ÿ‘๏ธ0
Frankestin Frankestin 10 months ago
Huh!
๐Ÿ‘๏ธ0
Frankestin Frankestin 10 months ago
https://clinicaltrials.gov/ct2/show/NCT05531786?cond=pacritinib&draw=2
Who knows if we will know some data before the closing of the deal?
๐Ÿ‘๏ธ0
Frankestin Frankestin 11 months ago
now we can spend!
https://clinicaltrials.gov/ct2/show/NCT05552183?cond=pacritinib&draw=2&rank=2
https://clinicaltrials.gov/ct2/history/NCT05552183
https://clinicaltrials.gov/ct2/show/NCT05657613?cond=pacritinib&draw=2&rank=3
https://clinicaltrials.gov/ct2/history/NCT05657613

How sad all the difficulties encountered for JB's cunning!
After all, those who pay the most are the sick since time is the most precious thing we have!

Is it possible that there is no one willing to up the ante a bit?
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 11 months ago
congrat$
๐Ÿ‘๏ธ0
herbied47 herbied47 11 months ago
Congrats longs!
๐Ÿ‘๏ธ0
Frankestin Frankestin 11 months ago
Sobi's got a deal!
If it goes wrong they take 59 million!
It could happen

In the event of a termination of the Merger Agreement under certain specified circumstances, including (i) termination by CTI to enter into an agreement providing for a Superior Offer (provided that CTI did not materially breach its non-solicitation obligations in any manner that results in such Superior Offer), (ii) termination by Sobi following a Company Adverse Recommendation Change, (iii) termination by Sobi due to the CTI board of directorsโ€™ failure to include its recommendation in the Schedule 14D-9, (iv) termination by Sobi because CTI has materially breached its obligations in respect of the non-solicitation provisions in the Merger Agreement, or (v) termination by either CTI or Sobi if the closing of the transactions contemplated by the Merger Agreement has not occurred by the Outside Date or termination by Sobi prior to the Offer Acceptance Time if CTI breaches its representations, warranties or covenants in the Merger Agreement in a way that would cause certain conditions of the Offer not to be satisfied (subject to CTIโ€™s right to cure the breach as set forth in the Merger Agreement prior to such time of termination), and (A) a bona fide โ€œAcquisition Proposalโ€ (as defined in the Merger Agreement) has been publicly disclosed after the date of the Merger Agreement and (B) within twelve months following such termination, CTI signs a definitive agreement for an Acquisition Proposal or consummates an Acquisition Proposal, in each case of the foregoing clauses (i)-(v), CTI is required to pay Sobi a termination fee equal to $59,000,000.
This summary is qualified in its entirety by reference to the Merger Agreement, which is filed as Exhibit 2.1 hereto and incorporated by reference herein.
๐Ÿ‘๏ธ0
Frankestin Frankestin 11 months ago
BOOM!
MANY THANKS TO ADAM!
The price seems low to me, let's hope someone raises it!
Congratulations to all who are enjoying!

๐Ÿ‘๏ธ0
Frankestin Frankestin 11 months ago
https://ascopubs.org/doi/pdfdirect/10.1200/PO.22.00523
๐Ÿ‘๏ธ0
Stumblebum Stumblebum 11 months ago
Hey HD did you buy any CTIC yetโ€ฆ..come Tuesday morning Iโ€™ll have 38k
๐Ÿ‘๏ธ0
Stumblebum Stumblebum 11 months ago
Ctic and gern might be mergingโ€ฆ.
๐Ÿ‘๏ธ0
Frankestin Frankestin 1 year ago
https://clinicaltrials.gov/ct2/show/NCT05531786?cond=pacritinib&draw=2
really started
๐Ÿ‘๏ธ0
Frankestin Frankestin 1 year ago
https://investors.ctibiopharma.com/static-files/83278a88-ff8f-457a-bccf-1900fe5042d8
๐Ÿ‘๏ธ0
Frankestin Frankestin 1 year ago
Why did they bring it up early in the morning?
seems unusual to me!
๐Ÿ‘๏ธ0
Frankestin Frankestin 1 year ago
FDA approval of VONJO (pacritinib) for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L.
$54 million in net sales in the first nine months following VONJO launch.
Over 1,000 patients commercially treated with VONJO in 2022.
Inclusion in the National Comprehensive Cancer Network® (NCCN®)
Oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition highlighted pacritinib as a potent activin A receptor type 1 (ACVR1) inhibitor with significant anemia benefit in patients with myelofibrosis. A receptor type 1 (ACVR1) inhibitor and anemia benefit. We look forward to continuing activities focused on market expansion in 2023, which are intended to drive quarter-over-quarter net sales increases
On February 7, 2023, VONJO was granted seven years of orphan-drug exclusive approval by the FDA for treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 x109/L. The seven-year exclusive approval began on February 28, 2022.
๐Ÿ‘๏ธ0
Frankestin Frankestin 1 year ago
https://investors.ctibiopharma.com/static-files/83278a88-ff8f-457a-bccf-1900fe5042d8
no sneak peeks on last quarter's sales
๐Ÿ‘๏ธ0
Frankestin Frankestin 1 year ago
Upcoming Events
SVB Securities Global Biopharma Conference
Feb 15, 2023 at 3:40 PM EST
Guggenheim Partners 5th Annual Oncology Conference
Feb 8, 2023 at 10:45 AM EST

Well, won't he say anything about the year that just ended?
๐Ÿ‘๏ธ0
Frankestin Frankestin 1 year ago
https://clinicaltrials.gov/ct2/show/NCT05657613?cond=pacritinib&draw=2&rank=3
Actual Study Start Date : January 3, 2023
๐Ÿ‘๏ธ0
Frankestin Frankestin 1 year ago
Net VONJO sales of $32.9M since launch in March 2022*
๐Ÿ‘๏ธ0
Frankestin Frankestin 1 year ago
tomorrow it's Adam Craig's turn with capsule therapy

https://investors.ctibiopharma.com/static-files/83278a88-ff8f-457a-bccf-1900fe5042d8
๐Ÿ‘๏ธ0
Frankestin Frankestin 1 year ago
https://clinicaltrials.gov/ct2/show/NCT05657613?cond=pacritinib&draw=2&rank=3
NEW
๐Ÿ‘๏ธ0
Frankestin Frankestin 1 year ago
started
https://clinicaltrials.gov/ct2/show/NCT05531786?cond=pacritinib&draw=2
๐Ÿ‘๏ธ0
Frankestin Frankestin 1 year ago
Stephen Oh, MD, PhD, Associate Professor of Medicine, Hematology Division at Washington University School of Medicine in St. Louis. "As anemia poses a substantial burden for patients with myelofibrosis, the potential role of pacritinib in addressing anemia is highly encouraging."

"As our understanding of the mechanism of action of pacritinib expands, the full potential of pacritinib as a therapy for cytopenic myelofibrosis is emerging," said Adam Craig, MD, PhD, President and Chief Executive Officer of CTI BioPharma. "We continue in our commitment to meaningfully change the treatment paradigm for cytopenic myelofibrosis."
๐Ÿ‘๏ธ0
Frankestin Frankestin 1 year ago
https://wsw.com/webcast/stifel74/register.aspx?conf=stifel74&page=ctic&url=https://wsw.com/webcast/stifel74/ctic/2075894
Today
๐Ÿ‘๏ธ0
Frankestin Frankestin 1 year ago
https://wsw.com/webcast/jeff255/ctic/1835973
i like Adam Craig
๐Ÿ‘๏ธ0
Frankestin Frankestin 1 year ago
who will buy today or tomorrow?
https://fintel.io/sst/us/ctic
๐Ÿ‘๏ธ0
Frankestin Frankestin 1 year ago
180 milion share outstanding
17 milion short!
I see it for $ 10 because PAC is the best
and the FDA are taking notice
JB was right
JB was right
JB was right
JB was right
JB was right
JB was right
JB was right
๐Ÿ‘๏ธ0
Frankestin Frankestin 1 year ago
Graig but why don't you propose to Pfizer to try PAC?
https://www.fiercepharma.com/pharma/europe-will-look-at-all-jak-inhibitors-following-safety-concerns-raised-trial-pfizer-s
๐Ÿ‘๏ธ0
Frankestin Frankestin 1 year ago
owls are in no hurry!
https://www.youtube.com/shorts/yPm0Yqx2mcE
๐Ÿ‘๏ธ0
Frankestin Frankestin 1 year ago
https://investors.ctibiopharma.com/static-files/83278a88-ff8f-457a-bccf-1900fe5042d8
๐Ÿ‘๏ธ0
Frankestin Frankestin 1 year ago
In the third quarter, CTI continued to make strong progress with the U.S. commercial laun ch of VONJO, delivering net revenue of $18.2 million, a 48% increase in sales compared to the second quarter.
๐Ÿ‘๏ธ0
Frankestin Frankestin 1 year ago
IMO, careful cost management will lead to higher margins
๐Ÿ‘๏ธ0
Frankestin Frankestin 1 year ago
made the due proportions...
INCY
Jakafiโ€™s (a first-in-class JAK1/JAK2 inhibitor approved for polycythemiavera, myelofibrosis and refractory acute graft-versus-host disease) revenues came in at $619.5 million.
Jakafi® (ruxolitinib) net product revenues of $598 million in Q2โ€™22 (+13% Y/Y) driven by volume growth; raising the bottom end of full year guidance to new range of $2.36 to $2.40 billion
๐Ÿ‘๏ธ0
Frankestin Frankestin 1 year ago
https://www.targetedonc.com/view/reactions-to-the-latest-data-on-jak-inhibition-for-myelofibrosis
Who knows what the plans are? nothing in europe?
Could PAC be used in the remautological space given the problem of other inhibitors?
liquid shit but maybe it's better than thrombotic events
๐Ÿ‘๏ธ0
Frankestin Frankestin 1 year ago
https://fintel.io/so/us/ctic
Institutional Shares (Long) 94,105,342 - 82.27%
Insider Ownership 13.84%

but someoneโ€ฆ.brrrrrr
https://fintel.io/sst/us/ctic
๐Ÿ‘๏ธ0
Frankestin Frankestin 1 year ago
https://fintel.io/so/us/ctic
Institutional Shares (Long) 94,105,342 - 82.27%
Insider Ownership 13.84%

but someoneโ€ฆ.brrrrrr
https://fintel.io/sst/us/ctic
๐Ÿ‘๏ธ0
Frankestin Frankestin 1 year ago
Jim Fong, the Companyโ€™s Chief Commercial Officer, has been promoted to Executive Vice President and Chief Commercial Officer, and will begin reporting directly to the Companyโ€™s Chief Executive Officer.
sounds good to me
Who knows why they promoted him?
๐Ÿ‘๏ธ0
Frankestin Frankestin 1 year ago
NEW
https://clinicaltrials.gov/ct2/show/NCT05552183?cond=pacritinib&draw=2&rank=2
๐Ÿ‘๏ธ0
Frankestin Frankestin 2 years ago
Pacritinib is a JAK2/IRAK1/CSF1R/FLT3 inhibitor, with an established safety and efficacy profile in the treatment of myeloproliferative neoplasms (myelofibrosis) and of acute GVHD.
Pacritinib s immunomodulatory effects suggest therapeutic benefit for cGVHD, without abrogating the graft-versus-leukemia effect after HSCT.
Start - 20
๐Ÿ‘๏ธ0
Frankestin Frankestin 2 years ago
NEW
https://clinicaltrials.gov/ct2/show/NCT05531786?cond=PACRITINIB&draw=3&rank=21
๐Ÿ‘๏ธ0
Frankestin Frankestin 2 years ago
https://investors.ctibiopharma.com/static-files/83278a88-ff8f-457a-bccf-1900fe5042d8
๐Ÿ‘๏ธ0
Frankestin Frankestin 2 years ago
https://clinicaltrials.gov/ct2/show/NCT04858256?cond=Pacritinib&draw=2&rank=1
it seems to be starting soon

https://clinicaltrials.gov/ct2/show/NCT02891603
what will they do?
๐Ÿ‘๏ธ0
Frankestin Frankestin 2 years ago
pacritinib sales will be strong!
the drug is used after ruxolitinib...
๐Ÿ‘๏ธ0
Frankestin Frankestin 2 years ago
Why is everything stopped? At least it seems
https://clinicaltrials.gov/ct2/show/NCT04858256?cond=pacritinib&draw=2&rank=1
๐Ÿ‘๏ธ0
Frankestin Frankestin 2 years ago

https://investors.ctibiopharma.com/static-files/83278a88-ff8f-457a-bccf-1900fe5042d8
๐Ÿ‘๏ธ0
bigbux1 bigbux1 2 years ago
Nice, $10 price target https://www.marketscreener.com/quote/stock/CTI-BIOPHARMA-CORP-32713095/news/Cowen-Starts-CTI-BioPharma-at-Outperform-With-10-Price-Target-40919991/
๐Ÿ‘๏ธ0
Frankestin Frankestin 2 years ago
here willing to recover! so much has been given it is time to receive
๐Ÿ‘๏ธ0
Frankestin Frankestin 2 years ago
Huh
7
Yeah!
๐Ÿ‘๏ธ0
Frankestin Frankestin 2 years ago
So the second quarter is closed! We will have a more realistic sales projection!
I imagine Robocop busy presenting them, always interesting how he frames things!
For the rest it seems to me that everything has stopped!
So something comes to me
๐Ÿ‘๏ธ0
Frankestin Frankestin 2 years ago
something makes me think of a BO
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock